MedWatch

Astrazeneca shot shows no increased clot risk after two doses

Blot clots are not more likely after second Astrazeneca jab, data published in The Lancet suggests.

Photo: Athit Perawongmetha/REUTERS / X02943

Astrazeneca's covid-19 vaccine doesn't raise the risk of a rare blood clotting disorder after a second dose, suggesting people shouldn't hesitate to get another one if they didn't have trouble after the first.

The estimated rate of the disorder, called thrombosis with thrombocytopenia syndrome (TTS), was 2.3 per million in people who received a second shot, according to data published in the medical journal The Lancet. That's comparable to what's found in an unvaccinated population. But the rate after a single dose was still higher, at 8.1 per million.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs